Pharma-Bio Industry Launches Construction of 212 North American Sites in 2022

October 20, 2022--Researched by Industrial Info Resources (Sugar Land, Texas)--The economy may be in an uproar, and the world cloaked in uncertainty, but Industrial Info's research group for the Pharmaceutical & Biotech Industry is tracking 213 North American new-build projects with a 2022 start date. Those projects represent a potential investment of more than $20 billion. The projects range from Cube Psytech's (Vancouver, British Columbia) $1 million psilocybin lab in Canada, to FUJIFILM Diosynth Biotechnologies' (Durham, North Carolina) $2 billion mega "Project Galaxy" in North Carolina. The traditional industry clusters on the east and west coasts are staying strong, but locations across the U.S. and Canada are sprouting up. Other Pharma-Bio projects tracked by Industrial Info include those from major companies such as Scorpion Biological Services, Spark Therapeutics Incorporated, Novartis AG (NYSE:NVS), Alexandria Real Estate Equities Incorporated, BioMed Realty and JLL (NYSE:JLL).